Forrest Powers
Rheumatology · Atlanta, GANPI 1235556366
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Argenx US, Inc. accounts for 61.1% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $7,339, more than ten times the $532 reported in 2019.
Across 279 payments — averaging $43.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$7K
- AbbVie$1K
- Johnson & Johnson$806
- Amgen$737
- UCB, Inc.$401
- Lilly USA, LLC$272
- plus $1K from 16 others
What the payments were for
- Consulting fees$6,50054%
- Travel & lodging$6946%
- Food & beverage$4,68739%
- Education$1321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 7 | $7,339 |
| AbbVie | 69 | $1,014 |
| Johnson & Johnson | 49 | $806 |
| Amgen(2 entities) | 43 | $737 |
| UCB, Inc. | 28 | $401 |
| Lilly USA, LLC | 13 | $272 |
| Novartis | 18 | $269 |
| E.r. Squibb & Sons, L.L.C. | 13 | $255 |
| Pfizer | 10 | $190 |
| AstraZeneca(2 entities) | 6 | $178 |
| Mallinckrodt Hospital Products Inc. | 5 | $144 |
| Boehringer Ingelheim | 4 | $97 |
| Nevro Corp. | 1 | $68 |
| GSK | 3 | $61 |
| Sobi, Inc | 2 | $41 |
| Aurinia Pharma U.S., Inc. | 2 | $36 |
| Mallinckrodt Enterprises LLC | 1 | $29 |
| Bristol Myers Squibb | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Pacira Therapeutics, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $13 |
| Medexus Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$6,500
- VYVGART HYTRULO$624
How this compares
$12,012 in reported general payments places this provider in the 65th percentile of 177 rheumatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 24 | $217,597 |
| Orencia ClickjectAbatacept | 11 | $73,310 |
| Hydroxychloroquine Sulfate | 82 | $3,253 |
| MethotrexateMethotrexate Sodium | 92 | $1,399 |
| Mycophenolate Mofetil | 28 | $924 |
| Pilocarpine Hcl | 14 | $901 |
| Prednisone | 144 | $784 |
| Leflunomide | 25 | $334 |
| Azathioprine | 12 | $267 |
| Celecoxib | 12 | $252 |
| Allopurinol | 23 | $174 |
| Folic Acid | 14 | $160 |
| Methylprednisolone | 25 | $143 |
| Sulfasalazine | 16 | $103 |
| Tramadol Hcl | 25 | $102 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Atlanta
- Gary MyersonAtlanta$1M
- William WilsonAtlanta$344K
- Paul SutejAtlanta$140K
- Sung LimAtlanta$125K
- Arezou KhosroshahiAtlanta$66K
- Kimberley WilsonAtlanta$41K
- John GoldmanAtlanta$33K
- Wambui MachuaAtlanta$31K
- Paula TanasaAtlanta$31K
- Rattandeep SinghAtlanta$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.